TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06413953: A Phase I Clinical Study of Tolerability and Pharmacokinetics of TQB3107 Tablets in Patients With Malignant Tumors

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,817,272

Rescue Site Savings

+$4,492,488

Unlock Full NCT06413953 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06413953 Rescue Dossier →